+1,292.0%
MRVL vs GSK
+183.6%
+1,108.4%
-91.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +9.3% | -1.2% | +10.6% | +9.8% |
| 7D | +5.6% | -1.1% | +6.7% | +6.2% |
| 30D | -36.5% | +7.8% | -44.4% | -38.8% |
| 3M | -20.5% | +0.3% | -20.8% | -21.3% |
| 6M | -1.1% | +3.4% | -4.6% | -4.8% |
| YTD | +99.0% | +5.9% | +93.1% | +88.7% |
| 1Y | +89.3% | +8.2% | +81.1% | +77.9% |
| 3Y | +211.6% | +65.3% | +146.4% | +129.8% |
| 5Y | +134.1% | +43.3% | +90.7% | +81.3% |
| 10Y | +1,293.1% | +102.9% | +1,190.2% | +790.4% |
| All | +1,292.0% | +183.6% | +1,108.4% | +552.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling